The abstract is read at the publisher; the summary is JClub's.
Expert histopathologic evaluation plus molecular testing resolved 966 of 994 (97.2%) ambiguous primary cutaneous melanocytic tumors, with long-term outcomes supporting clinical validity.
- Why it matters: Ambiguous histology can block reliable benign-versus-malignant classification, risking mismanagement; this study tests whether a stepwise expert-and-molecular approach yields dependable diagnoses.
- What they did: In a Netherlands prospective cohort (Sept 2018–Dec 2021), 994 consecutive patients with ambiguous primary tumors underwent expert review, then next-generation sequencing, SNP array, and targeted RNA sequencing when inconclusive.
- The result: No melanoma-related events occurred in 608 nonmelanoma cases over median 5.4 years, while 20 of 358 melanoma cases developed events over median 5.0 years; none occurred in 28 borderline cases.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.